Please login to the form below

Not currently logged in
Email:
Password:

BMS teams up with Infinity Pharmaceuticals for Opdivo study

Will test dual therapy potential in targeting tumour resistance to checkpoint inhibitors

BMSBristol-Myers Squibb and Infinity Pharmaceuticals have teamed up to study tumour resistance to checkpoint inhibitors in BMS' immuno-oncology drug Opdivo (nivolumab).

The partners are due to begin their clinical trial collaboration before the end of the year, when they will combine Opdivo with Infinity's candidate IPI-549 to evaluate its potential for improving sustained efficacy and tolerability beyond the current standard of care.

Preclinical data for IPI-549 - which is currently in phase I trials as a monotherapy - has suggested that the drug candidate may not only enhance the effects of checkpoint inhibitors like Opdivo, but also reverse tumour resistance.

Designed to target immune cells, IPI-549 alters the immune-suppressive microenvironment that fosters tumour growth and promotes an anti-tumour immune response.

Dr Fouad Namouni, head of oncology development at BMS, said: “Targeting the tumour microenvironment is an important part of our immuno-oncology strategy as we continue to advance research for cancers with limited treatment options.

“Our agreement with Infinity builds on our continued focus to bring forward potential novel combination treatment options for patients with cancer.”

With a view to treating all patients with advanced forms of solid tumours, the study will begin with trials in non-small cell lung cancer (NSCLC), melanoma and squamous cell carcinoma of the head and neck (SCCHN), which account for 17% of all new cancer cases in the US each year.

BMS will be looking to the combination therapy to give its PD-1 inhibitor an advantage in the hyper-competitive immuno-oncology market, particularly after Opdivo failed to outperform Merck & Co's Keytruda (pembrolizumab) in a first-line NSCLC study earlier this year.

In that study Merck's Keytruda proved to better both progression-free and overall survival in NSCLC patients compared to standard chemotherapy and it was followed by an accelerated approval by the FDA last month.

Meanwhile, Roche's own PD-1 inhibitor Tecentriq (atezolizumab) has also been approved in NSCLC albeit as a second-line therapy and is currently undergoing a phase III trial for first-line use.

Article by
Rebecca Clifford

10th November 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics